The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
The Role Of The Acute Phase Response In Docetaxel Resistance In Hormone-refractory Prostate Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$74,365.00
Summary
Prostate cancer is the most common cancer in Australian men. Chemotherapy is used in advanced disease, but is only effective in ~50% of patients. In the first year of my PhD, I identified 8 plasma biomarkers that predict chemotherapy resistance. I plan to characterise how these immune molecules cause chemotherapy resistance using a mouse model of advanced prostate cancer. These markers may allow us to personalise prostate cancer treatment in the future and identify more effective therapies.